Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors

被引：0

作者：

Carneiro, Benedito A.

Safran, Howard

Beck, J. Thaddeus Thaddeus

Hamid, Omid

Spira, Alexander I.

Savvides, Panos

Gutierrez, Martin

Zhao, Yujie

Abbruzzese, James L.

Ward, Jeffrey P.

Weroha, Saravut John

Harris, Loleta D.

Kent, Sean

Pierceall, William

Skoura, Athanasia

Zheng, Jenny

Kern, Kenneth Alan

Thomas, Jacob Stephen

Santana-Davila, Rafael

机构：

[1] Brown Univ, Legorreta Canc Ctr, Providence, RI USA

[2] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA

[3] Highlands Oncol, Springdale, AR USA

[4] Angeles Clin & Res Inst, Cedars Sinai Affiliate, Los Angeles, CA USA

[5] Virginia Canc Specialists, Fairfax, VA USA

[6] Mayo Clin, Phoenix, AZ USA

[7] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA

[8] Mayo Clin Florida, Jacksonville, FL USA

[9] Duke Canc Inst, Durham, NC USA

[10] Washington Univ, Sch Med, St Louis, MO USA

[11] Mayo Clin, Rochester, MN USA

[12] Pfizer Inc, Houston, TX USA

[13] Pfizer Inc, Cambridge, MA USA

[14] Pfizer Inc, Summit, NJ USA

[15] Pfizer, Oncol Res & Dev, Penn Valley, PA USA

[16] Pfizer Inc, Collegeville, PA USA

[17] Pfizer Inc, San Diego, CA USA

[18] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[19] Univ Washington, Div Med Oncol, Dept Med, Seattle, WA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2529

引用

页数：1